ID   NCI-H929B
AC   CVCL_M400
DR   cancercelllines; CVCL_M400
DR   Wikidata; Q54908143
RX   PubMed=19830855;
CC   Population: Caucasian.
CC   Characteristics: Produces IgA kappa.
CC   Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1600 ! NCI-H929
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 14
//
RX   PubMed=19830855; DOI=10.3785/j.issn.1008-9292.2009.05.003;
RA   Zhu R., Xi H., Li Y.-H., Jiang H., Zou J.-F., Hou J.;
RT   "Establishment of a bortezomib-resistant myeloma cell line and
RT   differential proteins analysis by MALDI-TOF-MS.";
RL   Zhejiang Da Xue Xue Bao Yi Xue Ban 38:445-452(2009).
//